Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer?
MDR-1, an established predictor for chemo-resistance, may also be a potent prognostic factor for outcome in patients with locally confined RCC. Moreover, MDR-1 expression seems to correlate with the differentiation of the RCC and thus its value as an objective measure of the degree of differentiation should be further explored.
The neuroimaging component of the NINDS AIREN criteria does not distinguish between older patients with and without poststroke dementia.